secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001193125-23-122129
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies receives Nasdaq bid price deficiency notice; board changes announced
--------------------------------------------------------------------------------

- Received Nasdaq notice on April 25, 2023 for minimum bid price below $1.00 for 30 consecutive days.
- Has 180 days until October 23, 2023 to regain compliance by closing at $1.00+ for 10 consecutive business days.
- If not cured, may transfer to Nasdaq Capital Market for additional 180-day grace period; failure could lead to delisting.
- Director Kathleen Reape resigned effective Nov 1, 2023 due to employer guidelines; Board to appoint successor.
- Board reconstituted with six directors; Reape moves from Class III to Class I to allow shareholder vote in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523122129/0001193125-23-122129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523122129/d406158d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-122129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer